ViroPharma Price Target Increased to $43.00 by Analysts at JMP Securities (VPHM)
Stock analysts at JMP Securities hoisted their price objective on shares of ViroPharma (NASDAQ:VPHM) from $38.00 to $43.00 in a report issued on Friday, Analyst Ratings.Net reports. JMP Securities’ price objective would suggest a potential upside of 10.26% from the stock’s previous close.
ViroPharma (NASDAQ:VPHM) traded up 0.48% on Friday, hitting $39.00. The stock had a trading volume of 815,007 shares. ViroPharma has a 52-week low of $22.12 and a 52-week high of $39.56. The stock’s 50-day moving average is $39.03 and its 200-day moving average is $31.49. The company’s market cap is $2.555 billion.
ViroPharma (NASDAQ:VPHM) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.20 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.05 by $0.15. The company had revenue of $113.00 million for the quarter, compared to the consensus estimate of $113.35 million. During the same quarter last year, the company posted $0.10 earnings per share. ViroPharma’s revenue was up 24.3% compared to the same quarter last year. On average, analysts predict that ViroPharma will post $-0.76 earnings per share for the current fiscal year.
A number of other firms have also recently commented on VPHM. Analysts at Cowen and Company raised their price target on shares of ViroPharma from $26.00 to $27.00 in a research note to investors on Friday. They now have a “market perform” rating on the stock. Separately, analysts at Zacks upgraded shares of ViroPharma from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, October 23rd. They now have a $46.00 price target on the stock. Finally, analysts at Mizuho downgraded shares of ViroPharma from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, October 9th. They now have a $39.00 price target on the stock. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $38.03.
ViroPharma Incorporated (NASDAQ:VPHM) is an international biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.